Part 5: Special Populations & Quality Metrics
PADIS management in special populations including post-operative, neurological injury, substance withdrawal (alcohol/CIWA, opioid/COWS), ECMO and CRRT dosing adjustments, plus quality metrics, bundle compliance measurement, and implementation strategies.
Special Populations
Post-Operative ICU Patients
Post-surgical patients admitted to the ICU present unique challenges in PADIS management due to acute surgical pain, anesthetic carryover effects, and high delirium risk, particularly in elderly patients and those undergoing cardiac or major abdominal surgery.1 2
Pain Management Considerations
| Principle | Details |
|---|---|
| Multimodal analgesia is the standard | Combine opioids with acetaminophen, NSAIDs (if not contraindicated), gabapentinoids, ketamine, and regional techniques |
| Regional anesthesia | Thoracic epidural for thoracotomy, major abdominal surgery; paravertebral or erector spinae plane blocks for rib fractures and chest wall procedures; peripheral nerve blocks for extremity procedures |
| Patient-controlled analgesia (PCA) | Appropriate for alert, cooperative post-operative patients; fentanyl 10–20 mcg q 6–10 min lockout or hydromorphone 0.2 mg q 8 min lockout (no continuous basal rate in opioid-naive patients) |
| Transition plan | Begin transitioning from IV to oral/enteral analgesics as soon as absorptive capacity allows; plan documented in post-operative orders |
Sedation Considerations
| Principle | Details |
|---|---|
| Light sedation targets | RASS 0 to −1 for most post-operative patients |
| Residual anesthetic effects | Account for intraoperative agents (propofol redistribution, long-acting opioids, neuromuscular blocker reversal); be patient before initiating new infusions |
| Early extubation | Prioritize rapid emergence and early extubation when clinically appropriate; avoid unnecessary sedation that delays this |
| Post-cardiac surgery | Fast-track protocols aim for extubation within 4–8 hours; dexmedetomidine may facilitate extubation; sternal precautions during mobility |
| Post-neurosurgery | Frequent neurologic assessments required; prefer agents with rapid offset (remifentanil, propofol, dexmedetomidine) to enable serial exams |
Delirium Prevention in Post-Operative Patients
| Strategy | Evidence |
|---|---|
| Perioperative dexmedetomidine | May reduce post-operative delirium incidence (conditional recommendation; strongest evidence in cardiac surgery)3 |
| Avoid benzodiazepines in premedication and post-operative sedation | Reduces delirium risk |
| Multicomponent non-pharmacologic bundle | Reorientation, early mobility (POD 0–1), sleep promotion, family presence |
| Minimize anticholinergic load | Review all medications; avoid diphenhydramine, promethazine for nausea |
| Preoperative risk assessment | Identify high-risk patients (age ≥ 65, cognitive impairment, frailty, alcohol use) for targeted prevention |
Neurological Injury
Patients with traumatic brain injury (TBI), stroke, subarachnoid hemorrhage (SAH), intracerebral hemorrhage, and status epilepticus require modified PADIS approaches that balance neurologic assessment needs with adequate analgesia and sedation.1 4
General Principles
| Principle | Details |
|---|---|
| Frequent neurologic exams | The need for serial, reliable neurologic assessments (GCS, pupillary reactivity, motor exam) drives sedation strategy — prefer agents with rapid offset |
| Sedation holds | “Neuro wake-up tests” — brief periods of sedation interruption for targeted neurologic assessment; timing and frequency per neurosurgical/neurology team |
| ICP management | In patients with intracranial hypertension, deeper sedation may be needed to reduce cerebral metabolic rate and ICP; propofol is preferred for its ICP-lowering properties |
| Seizure management | Benzodiazepines remain first-line for active seizures; propofol and midazolam infusions for refractory status epilepticus |
| Avoid hypotension | Cerebral perfusion pressure (CPP = MAP − ICP) must be maintained; sedative-induced hypotension is particularly harmful |
Agent Selection in Neurological Injury
| Agent | Role in Neuro ICU | Considerations |
|---|---|---|
| Propofol | First-line sedation for most neuro ICU patients | Reduces ICP; rapid offset for neuro exams; dose-dependent hypotension (maintain CPP); PRIS risk — limit dose and duration |
| Remifentanil | Excellent for frequent neuro wake-up tests | Ultra-short offset (3–10 min); no accumulation; allows rapid transition from deep sedation to examination; may cause acute opioid tolerance |
| Fentanyl | Standard opioid analgesia | Minimal effect on ICP when ventilation is controlled; avoid rapid large boluses (theoretical ICP concern from transient hypotension) |
| Dexmedetomidine | Useful for light sedation; facilitates neuro exams without full awakening | Arousable sedation; no respiratory depression; may be used as adjunct to propofol; limited depth of sedation |
| Ketamine | Adjunct for refractory ICP or as propofol-sparing agent | Recent evidence supports safety in TBI with controlled ventilation; no significant ICP increase; may have neuroprotective properties; reduces propofol/opioid requirements |
| Midazolam | Refractory status epilepticus; rarely for routine neuro ICU sedation | Unreliable offset; accumulates; increases delirium risk; reserve for seizure management |
| Pentobarbital | Refractory intracranial hypertension; super-refractory status epilepticus | Potent ICP reduction; severe hemodynamic depression; immunosuppression; very prolonged offset (days); requires continuous EEG and hemodynamic monitoring |
Delirium Assessment in Neurological Injury
- The CAM-ICU has been validated in brain-injured patients, though sensitivity may be lower
- The CPOT (pain assessment) has also been validated in this population
- Distinguishing delirium from primary neurologic deficit can be challenging — fluctuation and inattention remain the core features
- Neuroimaging and EEG may be needed to exclude non-convulsive seizures mimicking delirium
Substance Withdrawal Syndromes
Alcohol Withdrawal in the ICU
Alcohol withdrawal syndrome (AWS) occurs in 8–31% of trauma admissions and 5–10% of all ICU admissions. It ranges from mild (tremor, anxiety, tachycardia) to life-threatening (delirium tremens, seizures, autonomic instability). Untreated severe alcohol withdrawal carries a mortality of 5–15%.5 6
Clinical Institute Withdrawal Assessment — Alcohol, Revised (CIWA-Ar) — Complete Scoring
The CIWA-Ar is a 10-item scoring tool used to assess the severity of alcohol withdrawal and guide pharmacologic treatment. Total score ranges from 0 to 67.5
| Item | Assessment | Scoring Range |
|---|---|---|
| 1. Nausea and vomiting | Ask: “Do you feel sick to your stomach? Have you vomited?” Observe. | 0 = no nausea or vomiting; 1–3 = mild nausea, no vomiting; 4 = intermittent nausea with dry heaves; 5–7 = constant nausea, frequent dry heaves or vomiting |
| 2. Tremor | Ask patient to extend arms and spread fingers. Observe. | 0 = no tremor; 1 = not visible, but felt fingertip to fingertip; 2–3 = moderate, with arms extended; 4 = severe, even without arms extended; 5–7 = severe, visible without patient effort |
| 3. Paroxysmal sweats | Observe | 0 = no sweat visible; 1 = barely perceptible sweating, palms moist; 2–3 = obvious beads of sweat on forehead; 4 = profuse sweating; 5–7 = drenching sweats |
| 4. Anxiety | Ask: “Do you feel nervous?” Observe. | 0 = no anxiety, at ease; 1 = mildly anxious; 2–3 = moderately anxious or guarded; 4 = equivalent to acute panic states; 5–7 = severe panic/terror |
| 5. Agitation | Observe | 0 = normal activity; 1 = somewhat more than normal activity; 2–3 = moderately fidgety and restless; 4 = paces back and forth or constantly thrashes; 5–7 = extreme agitation |
| 6. Tactile disturbances | Ask: “Do you have any itching, pins and needles, burning, or numbness, or do you feel bugs crawling on or under your skin?” | 0 = none; 1 = mild itching, pins and needles, burning, numbness; 2 = mild itching, pins and needles, burning, numbness; 3 = moderate itching, pins and needles, burning, numbness; 4 = moderately severe hallucinations; 5 = severe hallucinations; 6–7 = continuous hallucinations |
| 7. Auditory disturbances | Ask: “Are you more aware of sounds around you? Are they harsh? Do they frighten you? Are you hearing anything that is disturbing to you? Are you hearing things you know are not there?” | 0 = not present; 1 = very mild harshness; 2 = mild harshness; 3 = moderate harshness; 4 = moderately severe hallucinations; 5 = severe hallucinations; 6–7 = continuous hallucinations |
| 8. Visual disturbances | Ask: “Does the light appear to be too bright? Is its color different? Does it hurt your eyes? Are you seeing anything that is disturbing to you? Are you seeing things you know are not there?” | 0 = not present; 1 = very mild sensitivity; 2 = mild sensitivity; 3 = moderate sensitivity; 4 = moderately severe hallucinations; 5 = severe hallucinations; 6–7 = continuous hallucinations |
| 9. Headache, fullness in head | Ask: “Does your head feel different? Does it feel like there is a band around your head?” Do NOT rate for dizziness or lightheadedness. | 0 = not present; 1 = very mild; 2 = mild; 3 = moderate; 4 = moderately severe; 5 = severe; 6–7 = extremely severe |
| 10. Orientation and clouding of sensorium | Ask: “What day is this? Where are you? Who am I?” | 0 = oriented and can do serial additions; 1 = cannot do serial additions or is uncertain about date; 2 = date uncertain by more than 2 days; 3 = disoriented for date by more than 2 days; 4 = disoriented for place and/or person |
CIWA-Ar Interpretation and Treatment Thresholds:
| CIWA-Ar Score | Severity | Management |
|---|---|---|
| < 8 | Minimal withdrawal | Monitor q 4–8 h; supportive care; thiamine, folate, multivitamin |
| 8–15 | Mild-to-moderate withdrawal | Monitor q 2–4 h; symptom-triggered benzodiazepine protocol; consider oral chlordiazepoxide or lorazepam |
| 16–20 | Moderate withdrawal | Monitor q 1–2 h; symptom-triggered dosing with frequent reassessment |
| > 20 | Severe withdrawal / impending delirium tremens | Aggressive pharmacologic treatment; ICU-level monitoring; IV benzodiazepines (lorazepam or diazepam) |
Limitations of CIWA-Ar in the ICU: The CIWA-Ar requires a patient who can communicate and participate. It is unreliable in intubated, deeply sedated, or delirious patients. In these cases, clinical assessment of autonomic signs (tachycardia, hypertension, fever, diaphoresis) and sedation scales (RASS, SAS) guide management.
Alcohol Withdrawal Pharmacotherapy in the ICU
| Agent | Route / Dose | Role | Considerations |
|---|---|---|---|
| Lorazepam | 1–4 mg IV q 15–30 min PRN (symptom-triggered) | First-line benzodiazepine for severe withdrawal | No active metabolites; hepatic glucuronidation (not oxidation) — safer in liver disease than diazepam; slower onset than diazepam |
| Diazepam | 5–20 mg IV q 5–15 min PRN for loading; then PRN | Alternative first-line; “front-loading” strategy | Rapid onset; long-acting active metabolites provide smoother withdrawal; avoid in severe hepatic dysfunction; greater risk of respiratory depression |
| Phenobarbital | 130–260 mg IV q 15–30 min PRN (max ~20 mg/kg loading) | Second-line; useful in benzodiazepine-resistant withdrawal | Synergistic with benzodiazepines (both GABA agonists but at different sites); slower onset; long half-life (useful for sustained effect); monitor for respiratory depression; narrow therapeutic index |
| Dexmedetomidine | 0.2–2.5 mcg/kg/h IV infusion (higher doses than standard sedation) | Adjunct for sympatholytic effects; reduces benzodiazepine requirements | Does NOT prevent seizures or treat delirium tremens — must be combined with GABAergic agent; reduces tachycardia, hypertension, anxiety; increasingly used in severe withdrawal7 |
| Propofol | 5–80 mcg/kg/min IV infusion | Refractory alcohol withdrawal not controlled by benzodiazepines + phenobarbital | GABAergic; effective for refractory cases; requires intubation; PRIS risk |
| Ketamine | 0.5–2 mg/kg/h IV infusion | Emerging adjunct for refractory withdrawal | NMDA antagonism may address kindling and neuronal excitotoxicity; reduces benzodiazepine and propofol requirements; limited evidence |
Supportive care for all alcohol withdrawal patients:
- Thiamine 500 mg IV q 8 h for 3 days (before glucose administration to prevent Wernicke encephalopathy), then 100 mg PO daily
- Folate 1 mg PO/IV daily
- Magnesium repletion (often depleted; target Mg > 2.0 mg/dL)
- Electrolyte monitoring and correction (K, Mg, Phos, Ca)
- IV fluid resuscitation as needed
- Glucose monitoring
Opioid Withdrawal in the ICU
Opioid withdrawal occurs in patients with chronic opioid use or dependence (including iatrogenic dependence from prolonged ICU opioid infusions ≥ 7 days) when opioids are abruptly discontinued or rapidly tapered. While not life-threatening, it causes significant distress and autonomic instability.1 8
Clinical Opiate Withdrawal Scale (COWS) — Complete Scoring
The COWS is an 11-item clinician-administered tool to assess the severity of opioid withdrawal. Total score ranges from 0 to 48.8
| Item | 0 | 1 | 2 | 3 | 4 | 5 |
|---|---|---|---|---|---|---|
| Resting pulse rate (measured after patient sitting/lying for 1 min) | ≤ 80 bpm | 81–100 | 101–120 | > 120 | — | — |
| Sweating (over past 30 min, not from room temperature or activity) | No report of chills or flushing | Subjective report of chills or flushing | Flushed or observable moisture on face | Beads of sweat on brow or face | Sweat streaming off face | — |
| Restlessness (observation during assessment) | Able to sit still | Reports difficulty sitting still but is able | Frequent shifting or extraneous movements of legs/arms | Unable to sit still for more than a few seconds | — | — |
| Pupil size | Pupils pinned or normal for room light | Pupils possibly larger than normal | Pupils moderately dilated | — | — | Pupils so dilated that only the rim of iris is visible |
| Bone or joint aches (if patient was having pain previously, judge only the additional component attributable to withdrawal) | Not present | Mild diffuse discomfort | Patient reports severe diffuse aching of joints/muscles | Patient rubbing joints or muscles and is unable to sit still because of discomfort | — | — |
| Runny nose or tearing (not from cold or allergies) | Not present | Nasal stuffiness or unusually moist eyes | Nose running or tearing | Nose constantly running or tears streaming down cheeks | — | — |
| GI upset (over past 30 min) | No GI symptoms | Stomach cramps | Nausea or loose stool | Vomiting or diarrhea | — | Multiple episodes of vomiting or diarrhea |
| Tremor (observation of outstretched hands) | No tremor | Tremor can be felt but not observed | Slight tremor observable | — | Gross tremor or muscle twitching | — |
| Yawning (observation during assessment) | No yawning | Yawning 1–2 times | Yawning 3+ times | — | Yawning several times per minute | — |
| Anxiety or irritability | None | Reports increasing anxiety/irritability | Obviously irritable or anxious | So anxious or irritable that participation is difficult | — | — |
| Gooseflesh skin | Skin is smooth | Piloerection of skin can be felt or hairs standing up on arms | Prominent piloerection | — | — | — |
COWS Interpretation:
| Score | Severity | Management |
|---|---|---|
| 5–12 | Mild withdrawal | Supportive care; consider clonidine or low-dose opioid |
| 13–24 | Moderate withdrawal | Pharmacologic treatment indicated |
| 25–36 | Moderately severe withdrawal | Aggressive pharmacologic treatment |
| > 36 | Severe withdrawal | Intensive pharmacologic management |
Opioid Withdrawal Management in the ICU
| Strategy | Details |
|---|---|
| Prevention | Taper opioid infusions by 10–20% per day after ≥ 5–7 days of continuous use; do NOT abruptly discontinue; convert to longer-acting enteral opioid (methadone or oral morphine equivalent) before taper when feasible |
| Methadone | 10–20 mg PO q 8–12 h initially; adjust based on COWS scoring; long half-life provides steady-state coverage; NMDA antagonist properties; monitor QTc |
| Buprenorphine | 2–4 mg SL q 6–8 h; must wait until COWS ≥ 8–12 before initiating (to avoid precipitated withdrawal); ceiling effect reduces overdose risk; partial mu agonist |
| Clonidine | 0.1–0.3 mg PO/transdermal q 8 h; treats autonomic symptoms (tachycardia, hypertension, diaphoresis, anxiety); does not treat cravings or subjective distress |
| Dexmedetomidine | 0.2–1.0 mcg/kg/h IV; similar mechanism to clonidine (alpha-2 agonist); IV route advantageous in ICU; treats autonomic symptoms |
| Symptomatic | Loperamide for diarrhea; ondansetron for nausea; acetaminophen/NSAIDs for myalgias; hydroxyzine or trazodone for insomnia (avoid benzodiazepines unless co-occurring withdrawal) |
Iatrogenic Withdrawal Prevention Protocol
For patients who have received continuous opioid and/or benzodiazepine infusions for ≥ 5 days:
| Step | Action |
|---|---|
| 1 | Calculate total daily opioid/benzodiazepine requirements from prior 24 hours |
| 2 | Convert to equivalent enteral dose (morphine PO or methadone; lorazepam PO) |
| 3 | Administer enteral equivalents in scheduled doses |
| 4 | Wean IV infusion by 10–20% per day |
| 5 | Once IV discontinued, taper enteral dose by 10–20% per day |
| 6 | Monitor for withdrawal signs (COWS for opioids; CIWA or clinical signs for benzodiazepines) |
| 7 | If withdrawal signs develop, hold taper for 24 hours, treat symptoms, then resume taper at slower rate |
ECMO and Sedation/Analgesia
Patients on extracorporeal membrane oxygenation (ECMO) present significant pharmacokinetic challenges for sedative and analgesic management.9
Drug Sequestration by ECMO Circuits
| Drug | Degree of Sequestration | Clinical Impact |
|---|---|---|
| Fentanyl | High (up to 70–97% lost to circuit) | Markedly increased dose requirements; lipophilic — binds to circuit tubing |
| Midazolam | High (up to 50–90%) | Significantly increased dose requirements |
| Propofol | Moderate-High (30–70%) | Increased dose requirements; high lipophilicity |
| Morphine | Low-Moderate (10–30%) | Less affected; hydrophilic |
| Dexmedetomidine | Moderate (20–50%) | Moderate dose adjustment needed |
| Ketamine | Low-Moderate | Less affected by circuit |
| Hydromorphone | Low-Moderate | Less sequestration than fentanyl |
Practical considerations:
- Expect 2–10× higher than normal doses of lipophilic drugs (fentanyl, midazolam, propofol)
- Titrate to clinical effect (RASS, BPS/CPOT) rather than using standard dose ranges
- Consider less lipophilic alternatives (hydromorphone instead of fentanyl; dexmedetomidine or ketamine for adjunct sedation)
- Drug loss is highest with new circuits and decreases as binding sites saturate
- Oxygenator replacement “resets” drug binding and may cause acute changes in drug levels
ECMO-Specific Sedation Strategy
| Phase | Goal | Approach |
|---|---|---|
| Cannulation | Deep sedation; prevent movement | Propofol bolus + infusion or ketamine bolus; ensure adequate neuromuscular blockade if needed |
| Early ECMO (0–48 h) | Deep sedation for cannula stability; especially with femoral cannulation | Fentanyl or hydromorphone infusion + propofol or dexmedetomidine; anticipate high dose requirements |
| Maintenance | Lightest sedation tolerated (RASS 0 to −2 when feasible) | Titrate down as patient stabilizes; goal is early rehabilitation even on ECMO; many centers now mobilize VV ECMO patients |
| Weaning/decannulation | Alert and cooperative | Rapid taper of sedation; dexmedetomidine useful for anxiolysis during decannulation |
Continuous Renal Replacement Therapy (CRRT) — Drug Dosing Adjustments
CRRT removes drugs based on molecular weight, protein binding, and volume of distribution. Adjustments to sedatives and analgesics may be needed.10
| Drug | Removal by CRRT | Dose Adjustment |
|---|---|---|
| Fentanyl | Minimal (highly protein-bound, large Vd) | No routine adjustment |
| Hydromorphone | Minimal-Moderate (active metabolite H3G may accumulate — CRRT removes some) | Monitor for neuroexcitation (myoclonus from H3G); may need dose reduction in prolonged use |
| Morphine | Moderate (M6G active metabolite removed by CRRT) | CRRT provides some M6G clearance — safer than no RRT, but still use with caution; consider alternative |
| Propofol | Minimal (highly protein-bound, lipophilic) | No routine adjustment |
| Midazolam | Minimal (highly protein-bound) | No routine dose adjustment for CRRT; but alpha-hydroxymidazolam may accumulate less with CRRT than with no RRT |
| Dexmedetomidine | Minimal (highly protein-bound) | No routine adjustment |
| Ketamine | Low | No routine adjustment |
| Gabapentin | Significantly removed by CRRT | Supplement 200–300 mg after each CRRT day or use 100–200 mg q 12 h during CRRT |
| Acetaminophen | Moderately removed | May need supplemental dosing; standard dosing usually adequate |
Burns and Trauma
| Consideration | Details |
|---|---|
| Massive opioid requirements | Burn patients often require 2–10× normal opioid doses due to upregulation of opioid receptors, ongoing tissue injury, and repeated painful procedures (dressing changes, debridement) |
| Ketamine | Particularly useful in burn patients — analgesic and dissociative properties useful for procedures; sympathomimetic properties support hemodynamics; reduces opioid requirements |
| Propofol | Caution in large-surface-area burns (may worsen hypertriglyceridemia from parenteral lipid nutrition) |
| Regional anesthesia | Useful when feasible for extremity burns and trauma |
| Anxiety and PTSD | High rates; non-pharmacologic interventions (music, VR distraction, family presence) important |
| Pharmacokinetic changes | Altered protein binding, increased volume of distribution, and enhanced hepatic clearance in hypermetabolic burn patients — anticipate higher dose requirements |
Quality Metrics and Implementation
ABCDEF Bundle Compliance Metrics
Tracking and reporting bundle compliance is essential for quality improvement and is associated with improved patient outcomes.11 12
Recommended Quality Metrics
| Metric | Target | Measurement Method |
|---|---|---|
| A — Pain assessment compliance | ≥ 90% of shifts with documented pain assessment using validated tool (BPS, CPOT, or NRS) | EMR audit: documented BPS, CPOT, or NRS at least once per nursing shift |
| B — SAT performed (when eligible) | ≥ 80% of eligible patient-days | EMR audit: SAT safety screen documented; SAT performed or contraindication documented |
| B — SBT performed (when eligible) | ≥ 80% of eligible patient-days | EMR audit: SBT safety screen documented; SBT performed or contraindication documented |
| B — SAT/SBT coordination | ≥ 70% coordination rate | SAT preceding SBT on same day |
| C — Light sedation achievement | ≥ 70% of assessments at RASS 0 to −2 (for patients without deep sedation indication) | EMR audit: RASS scores; percentage at target |
| C — Benzodiazepine avoidance | < 10% of sedation days using benzodiazepine infusion as primary sedative | Pharmacy audit: midazolam or lorazepam infusion hours |
| D — Delirium screening compliance | ≥ 90% of shifts with documented CAM-ICU or ICDSC | EMR audit: delirium screening documentation |
| D — Delirium prevalence | Track and trend (no specific target — goal is reduction over time) | Percentage of patient-days with positive CAM-ICU or ICDSC ≥ 4 |
| E — Early mobility compliance | ≥ 70% of eligible patient-days with documented mobilization event | EMR/PT documentation: mobility level achieved; duration |
| E — Highest mobility level achieved | Track and trend (goal: progressive improvement) | Median mobility level per patient per day |
| F — Family engagement | ≥ 80% of patients with documented family communication within 48 hours of admission | EMR audit: social work/nursing documentation of family contact |
Composite Bundle Compliance
| Measure | Calculation |
|---|---|
| Full bundle compliance (all-or-none) | Percentage of eligible patient-days where ALL applicable bundle elements (A through F) were completed |
| Proportional compliance | Average percentage of individual bundle elements completed per patient-day |
The ICU Liberation Collaborative demonstrated that each 10% increase in proportional compliance was associated with significant improvements in delirium, coma, ventilator-free days, and survival.11
Data Collection and Reporting
| Element | Recommendation |
|---|---|
| Frequency | Daily data collection; weekly or monthly aggregate reporting |
| Dashboard | Real-time or near-real-time display of bundle compliance visible to all ICU staff (electronic dashboard, whiteboard, or huddle report) |
| Benchmarking | Compare performance against internal trends and external benchmarks (ICU Liberation Collaborative data) |
| Feedback | Share results with frontline clinicians at regular intervals (weekly huddles, monthly quality meetings); include both compliance rates and patient outcomes |
| Case review | Review individual cases of prolonged delirium, ICUAW, prolonged ventilation for bundle compliance and opportunities |
Implementation Science: Strategies for Sustained Bundle Adoption
| Strategy | Details |
|---|---|
| Interprofessional champion model | Identify physician, nurse, RT, PT, and pharmacist champions on each unit; champions lead education, troubleshoot barriers, and model best practices |
| Standardized order sets | Embed bundle elements into admission order sets (sedation target selection, SAT/SBT protocol activation, delirium screening frequency, PT/OT consult, sleep protocol, family communication) |
| Education | Initial training for all ICU staff on assessment tools (hands-on practice with CAM-ICU, BPS/CPOT, RASS); competency validation; annual refresher |
| Daily multidisciplinary rounds | Structured rounding checklist that explicitly addresses each bundle element; “ABCDEF” as rounding framework |
| Nurse-driven protocols | Empower nurses to initiate SAT, mobilization, and sleep protocols without requiring individual physician orders (standing protocols) |
| Family engagement tools | Family information brochures; ICU diaries; structured family meetings; designation of family liaison |
| IT integration | EMR-embedded screening tools; automated reminders for overdue assessments; clinical decision support for sedation titration |
| Audit and feedback cycles | Plan-Do-Study-Act (PDSA) cycles for each bundle element; track compliance and outcomes; adjust strategies based on data |
| Leadership support | ICU medical director and nursing director visible support; protected time for champions; resource allocation for mobility equipment and staffing |
Common Pitfalls and Solutions
| Pitfall | Solution |
|---|---|
| CAM-ICU performed incorrectly (especially Feature 2 letters test) | Standardized training with video; competency testing; periodic inter-rater reliability checks |
| SAT not performed due to safety screen misinterpretation | Clearly define safety screen criteria; require documentation of specific reason when SAT is withheld |
| Deep sedation maintained longer than indicated | Daily sedation target review on rounds; require documentation of indication for deep sedation |
| Mobility deferred due to “patient too sick” | Standardized safety criteria (not physician gestalt); demonstrate Level 1–2 activities possible for most patients; PT/OT at bedside daily |
| Sleep protocol not followed overnight | Night-shift specific education; quiet time enforcement by charge nurse; sleep bundle compliance tracked separately |
| Antipsychotics continued at discharge without plan | Discharge medication reconciliation — flag any antipsychotic started in ICU; require documented indication and taper plan |
| Benzodiazepine used as first-line sedation by habit | Pharmacy alert for benzodiazepine infusion orders; require documentation of indication; peer review of benzodiazepine use rates |
Post-ICU Follow-Up
Survivors of critical illness are at risk for long-term physical, cognitive, and psychological impairment — collectively termed post-intensive care syndrome (PICS). The PADIS bundle aims to mitigate PICS, but follow-up care is also important.13
| PICS Domain | Prevalence at 12 Months | Screening / Follow-Up |
|---|---|---|
| Cognitive impairment | 25–34% | Neuropsychological testing; cognitive rehabilitation referral; occupational therapy |
| Physical disability | 25–50% | Functional assessment (6-minute walk test, grip strength); physical therapy; rehabilitation |
| Psychological | PTSD 10–25%; Depression 25–30%; Anxiety 30–40% | Screening questionnaires (PHQ-9, PCL-5, GAD-7); psychology/psychiatry referral; peer support groups |
Post-ICU clinic recommendations:
- Follow-up at 2–4 weeks, 3 months, and 12 months after ICU discharge
- Screen for all PICS domains
- Coordinate rehabilitation services
- Family/caregiver assessment and support
- Medication reconciliation (taper/discontinue ICU-initiated medications)
References
Devlin JW, Skrobik Y, Gélinas C, et al. “Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.” Crit Care Med. 2018;46(9):e825-e873. DOI: 10.1097/CCM.0000000000003299 ↩︎ ↩︎ ↩︎
Aldecoa C, Bettelli G, Bilotta F, et al. “European Society of Anaesthesiology Evidence-Based and Consensus-Based Guideline on Postoperative Delirium.” Eur J Anaesthesiol. 2017;34(4):192-214. DOI: 10.1097/EJA.0000000000000594 ↩︎
Duan X, Coburn M, Rossaint R, Sanders RD, Waesberghe JV, Kowark A. “Efficacy of Perioperative Dexmedetomidine on Postoperative Delirium: Systematic Review and Meta-Analysis with Trial Sequential Analysis of Randomised Controlled Trials.” Br J Anaesth. 2018;121(2):384-397. DOI: 10.1016/j.bja.2018.04.046 ↩︎
Oddo M, Crippa IA, Mehta S, et al. “Optimizing Sedation in Patients with Acute Brain Injury.” Crit Care. 2016;20:128. DOI: 10.1186/s13054-016-1294-5 ↩︎
Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. “Assessment of Alcohol Withdrawal: The Revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar).” Br J Addict. 1989;84(11):1353-1357. DOI: 10.1111/j.1360-0443.1989.tb00737.x ↩︎ ↩︎
Breshears EM, Ma S, Gong MN, et al. “Alcohol Withdrawal Syndrome in Critically Ill Patients: A Narrative Review.” Chest. 2022;162(3):649-663. DOI: 10.1016/j.chest.2022.04.146 ↩︎
Beg M, Fisher S, Siu D. “Treatment of Alcohol Withdrawal Syndrome with and without Dexmedetomidine.” Perm J. 2016;20(2):49-53. DOI: 10.7812/TPP/15-113 ↩︎
Wesson DR, Ling W. “The Clinical Opiate Withdrawal Scale (COWS).” J Psychoactive Drugs. 2003;35(2):253-259. DOI: 10.1080/02791072.2003.10400007 ↩︎ ↩︎
Shekar K, Fraser JF, Smith MT, Roberts JA. “Pharmacokinetic Changes in Patients Receiving Extracorporeal Membrane Oxygenation.” J Crit Care. 2012;27(6):741.e9-741.e18. DOI: 10.1016/j.jcrc.2012.02.013 ↩︎
Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. “The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients.” Clin Pharmacokinet. 2011;50(2):99-110. DOI: 10.2165/11539220-000000000-00000 ↩︎
Pun BT, Balas MC, Barnes-Daly MA, et al. “Caring for Critically Ill Patients with the ABCDEF Bundle: Results of the ICU Liberation Collaborative in Over 15,000 Adults.” Crit Care Med. 2019;47(1):3-14. DOI: 10.1097/CCM.0000000000003482 ↩︎ ↩︎
Barnes-Daly MA, Phillips G, Ely EW. “Improving Hospital Survival and Reducing Brain Dysfunction at Seven California Community Hospitals: Implementing PAD Guidelines Via the ABCDEF Bundle in 6,064 Patients.” Crit Care Med. 2017;45(2):171-178. DOI: 10.1097/CCM.0000000000002149 ↩︎
Needham DM, Davidson J, Cohen H, et al. “Improving Long-Term Outcomes After Discharge From Intensive Care Unit: Report From a Stakeholders’ Conference.” Crit Care Med. 2012;40(2):502-509. DOI: 10.1097/CCM.0b013e318232da75 ↩︎